Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors

Jeanne M. Sisk, Matthew B. Frieman, Carolyn E Machamer

Research output: Contribution to journalArticle

Abstract

Enveloped viruses gain entry into host cells by fusing with cellular membranes, a step that is required for virus replication. Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and infectious bronchitis virus (IBV), fuse at the plasma membrane or use receptor-mediated endocytosis and fuse with endosomes, depending on the cell or tissue type. The virus spike (S) protein mediates fusion with the host cell membrane. We have shown previously that an Abelson (Abl) kinase inhibitor, imatinib, significantly reduces SARS-CoV and MERS-CoV viral titres and prevents endosomal entry by HIV SARS S and MERS S pseudotyped virions. SARSCoV and MERS-CoV are classified as BSL-3 viruses, which makes experimentation into the cellular mechanisms involved in infection more challenging. Here, we use IBV, a BSL-2 virus, as a model for studying the role of Abl kinase activity during coronavirus infection. We found that imatinib and two specific Abl kinase inhibitors, GNF2 and GNF5, reduce IBV titres by blocking the first round of virus infection. Additionally, all three drugs prevented IBV S-induced syncytia formation prior to the hemifusion step. Our results indicate that membrane fusion (both virus–cell and cell–cell) is blocked in the presence of Abl kinase inhibitors. Studying the effects of Abl kinase inhibitors on IBV will be useful in identifying the host cell pathways required for coronavirus infection. This will provide an insight into possible therapeutic targets to treat infections by current as well as newly emerging coronaviruses.

Original languageEnglish (US)
Article number001047
Pages (from-to)619-630
Number of pages12
JournalJournal of General Virology
Volume99
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Infectious bronchitis virus
Coronavirus
Protein S
Phosphotransferases
Coronavirus Infections
Severe Acute Respiratory Syndrome
Viruses
Cell Membrane
Virus Internalization
Membrane Fusion
Endosomes
Virus Diseases
Giant Cells
Virus Replication
Endocytosis
Infection
Viral Load
Virion
HIV
Membranes

Keywords

  • Abl kinase
  • Abl1
  • Abl2
  • Cell-cell fusion
  • Coronavirus
  • GNF2
  • GNF5
  • IBV
  • Imatinib
  • MERS-CoV
  • SARS-CoV
  • Virus-cell fusion

ASJC Scopus subject areas

  • Virology

Cite this

Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. / Sisk, Jeanne M.; Frieman, Matthew B.; Machamer, Carolyn E.

In: Journal of General Virology, Vol. 99, No. 5, 001047, 01.05.2018, p. 619-630.

Research output: Contribution to journalArticle

@article{59cb2c0f213f4cf9849a91554891bf9f,
title = "Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors",
abstract = "Enveloped viruses gain entry into host cells by fusing with cellular membranes, a step that is required for virus replication. Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and infectious bronchitis virus (IBV), fuse at the plasma membrane or use receptor-mediated endocytosis and fuse with endosomes, depending on the cell or tissue type. The virus spike (S) protein mediates fusion with the host cell membrane. We have shown previously that an Abelson (Abl) kinase inhibitor, imatinib, significantly reduces SARS-CoV and MERS-CoV viral titres and prevents endosomal entry by HIV SARS S and MERS S pseudotyped virions. SARSCoV and MERS-CoV are classified as BSL-3 viruses, which makes experimentation into the cellular mechanisms involved in infection more challenging. Here, we use IBV, a BSL-2 virus, as a model for studying the role of Abl kinase activity during coronavirus infection. We found that imatinib and two specific Abl kinase inhibitors, GNF2 and GNF5, reduce IBV titres by blocking the first round of virus infection. Additionally, all three drugs prevented IBV S-induced syncytia formation prior to the hemifusion step. Our results indicate that membrane fusion (both virus–cell and cell–cell) is blocked in the presence of Abl kinase inhibitors. Studying the effects of Abl kinase inhibitors on IBV will be useful in identifying the host cell pathways required for coronavirus infection. This will provide an insight into possible therapeutic targets to treat infections by current as well as newly emerging coronaviruses.",
keywords = "Abl kinase, Abl1, Abl2, Cell-cell fusion, Coronavirus, GNF2, GNF5, IBV, Imatinib, MERS-CoV, SARS-CoV, Virus-cell fusion",
author = "Sisk, {Jeanne M.} and Frieman, {Matthew B.} and Machamer, {Carolyn E}",
year = "2018",
month = "5",
day = "1",
doi = "10.1099/jgv.0.001047",
language = "English (US)",
volume = "99",
pages = "619--630",
journal = "Journal of General Virology",
issn = "0022-1317",
publisher = "Society for General Microbiology",
number = "5",

}

TY - JOUR

T1 - Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors

AU - Sisk, Jeanne M.

AU - Frieman, Matthew B.

AU - Machamer, Carolyn E

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Enveloped viruses gain entry into host cells by fusing with cellular membranes, a step that is required for virus replication. Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and infectious bronchitis virus (IBV), fuse at the plasma membrane or use receptor-mediated endocytosis and fuse with endosomes, depending on the cell or tissue type. The virus spike (S) protein mediates fusion with the host cell membrane. We have shown previously that an Abelson (Abl) kinase inhibitor, imatinib, significantly reduces SARS-CoV and MERS-CoV viral titres and prevents endosomal entry by HIV SARS S and MERS S pseudotyped virions. SARSCoV and MERS-CoV are classified as BSL-3 viruses, which makes experimentation into the cellular mechanisms involved in infection more challenging. Here, we use IBV, a BSL-2 virus, as a model for studying the role of Abl kinase activity during coronavirus infection. We found that imatinib and two specific Abl kinase inhibitors, GNF2 and GNF5, reduce IBV titres by blocking the first round of virus infection. Additionally, all three drugs prevented IBV S-induced syncytia formation prior to the hemifusion step. Our results indicate that membrane fusion (both virus–cell and cell–cell) is blocked in the presence of Abl kinase inhibitors. Studying the effects of Abl kinase inhibitors on IBV will be useful in identifying the host cell pathways required for coronavirus infection. This will provide an insight into possible therapeutic targets to treat infections by current as well as newly emerging coronaviruses.

AB - Enveloped viruses gain entry into host cells by fusing with cellular membranes, a step that is required for virus replication. Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and infectious bronchitis virus (IBV), fuse at the plasma membrane or use receptor-mediated endocytosis and fuse with endosomes, depending on the cell or tissue type. The virus spike (S) protein mediates fusion with the host cell membrane. We have shown previously that an Abelson (Abl) kinase inhibitor, imatinib, significantly reduces SARS-CoV and MERS-CoV viral titres and prevents endosomal entry by HIV SARS S and MERS S pseudotyped virions. SARSCoV and MERS-CoV are classified as BSL-3 viruses, which makes experimentation into the cellular mechanisms involved in infection more challenging. Here, we use IBV, a BSL-2 virus, as a model for studying the role of Abl kinase activity during coronavirus infection. We found that imatinib and two specific Abl kinase inhibitors, GNF2 and GNF5, reduce IBV titres by blocking the first round of virus infection. Additionally, all three drugs prevented IBV S-induced syncytia formation prior to the hemifusion step. Our results indicate that membrane fusion (both virus–cell and cell–cell) is blocked in the presence of Abl kinase inhibitors. Studying the effects of Abl kinase inhibitors on IBV will be useful in identifying the host cell pathways required for coronavirus infection. This will provide an insight into possible therapeutic targets to treat infections by current as well as newly emerging coronaviruses.

KW - Abl kinase

KW - Abl1

KW - Abl2

KW - Cell-cell fusion

KW - Coronavirus

KW - GNF2

KW - GNF5

KW - IBV

KW - Imatinib

KW - MERS-CoV

KW - SARS-CoV

KW - Virus-cell fusion

UR - http://www.scopus.com/inward/record.url?scp=85046402518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046402518&partnerID=8YFLogxK

U2 - 10.1099/jgv.0.001047

DO - 10.1099/jgv.0.001047

M3 - Article

C2 - 29557770

AN - SCOPUS:85046402518

VL - 99

SP - 619

EP - 630

JO - Journal of General Virology

JF - Journal of General Virology

SN - 0022-1317

IS - 5

M1 - 001047

ER -